COVID-19

 

The Rheumatology Network COVID-19 clinical focus page provides information on the latest COVID-19 news, study and clinical trial findings, and clinical guideline updates for the treatment of COVID-19. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for COVID-19 drugs.

How COVID-19 Has Altered Assessment and Treatment of Osteoporosis

February 15, 2021

A study published in Osteoporosis International focused on the changes that have occurred over the course of the pandemic for patients with osteoporosis and found that there have been delays in dual-energy X-ray absorptiometry (DXA) scanning, problems with medication supply, a decrease in face-to-face consultations, and reductions in parenteral medication delivery.

Tocilizumab Does Not Improve Outcomes for Patients With Severe COVID-19

February 03, 2021

Tocilizumab is an interleukin 6 (an inflammatory cytokine) inhibitor approved for treating a variety of rheumatic diseases, including rheumatoid arthritis. As studies have shown that an increased level of interleukin 6 directly correlates to poor COVID-19 outcomes, investigators speculated that blocking this activity could be a helpful tool in treating the virus and lessening its severity.

Alice Fike, MS, NP: Latino Patients Disproportionately Affected by COVID-19

February 02, 2021

This week, we sat down for an interview with Alice Fike, MS, NP, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), to discuss her study titled “Risk factors for COVID-19 and rheumatic disease flare in a US cohort of Latino patients.” The primary objective of this retrospective study was to understand why Latino patients were being disproportionately affected by coronavirus disease 2019 (COVID-19).

Latino Patients With Rheumatic Diseases are at Higher Risk of Contracting COVID-19

February 01, 2021

The primary objective of this retrospective study was to understand why Latino patients were being disproportionately affected by COVID-19. Of the patients observed, 32 (18%) developed COVID-19 during the study period, meaning incidence rates were 5- to 11-fold higher than the general population (1,540 to 3,431/100,000).

April Jorge, MD: Improved COVID-19 Outcomes for Patients With Rheumatic Disease

January 29, 2021

This week, we sat down for an interview with April Jorge, MD, to discuss the findings of her study, “Temporal trends and severe COVID-19 outcomes in patients with rheumatic disease,” and what this may mean for patients with rheumatic disease moving forward in the pandemic.

Improved COVID-19 Outcomes for Patients With Rheumatic Diseases

January 20, 2021

Investigators found "improved outcomes for patients with rheumatic and musculoskeletal diseases after COVID-19 diagnosis in more recent months of the pandemic compared with earlier months, including lower risks of death, respiratory failure, and renal failure."

How Pharmaceutical Innovation Is Saving the World

January 05, 2021

The US and the world must appreciate the role of the pharmaceutical industry—the investigators, physicians and business leaders—who are rescuing the world from COVID-19. It’s the medical breakthrough of our lifetime.

Managing Rheumatic Disease Patients During the COVID-19 Pandemic

December 17, 2020

In this episode of Overdrive, the Rheumatology Network podcast, Dr. Kim Gorgens interviews Shereen Mahmood, MD, a rheumatologist with the Montefiore Medical Center in South Bronx, New York, to discuss her experience as a physician during the COVID-19 pandemic.

Rheumatic Disease Patients Still Need Pandemic Treatment Counsel

November 05, 2020

A survey of 9,004 patients with rheumatic disease―both autoimmune-related and non-autoimmune―shows that patients may need continued medication counseling through the duration of the pandemic, finds a study due to be presented on Friday at the American College of Rheumatology.